April 2014
Volume 55, Issue 13
ARVO Annual Meeting Abstract  |   April 2014
Biocompatibility of MedinGel biodegradable drug delivery system in the eye
Author Affiliations & Notes
  • Marta Spis
    MedinCell, Jacou, France
  • Laurence FERAILLE
    Iris Pharma, La Gaude, France
  • Sophie Antonelli
    Iris Pharma, La Gaude, France
  • Nicolas Cimbolini
    Iris Pharma, La Gaude, France
  • Pierre-Paul Elena
    Iris Pharma, La Gaude, France
  • Georges Gaudriault
    MedinCell, Jacou, France
  • Audrey Petit
    MedinCell, Jacou, France
  • Footnotes
    Commercial Relationships Marta Spis, None; Laurence FERAILLE, None; Sophie Antonelli, None; Nicolas Cimbolini, None; Pierre-Paul Elena, None; Georges Gaudriault, None; Audrey Petit, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science April 2014, Vol.55, 5273. doi:
  • Views
  • Share
  • Tools
    • Alerts
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Marta Spis, Laurence FERAILLE, Sophie Antonelli, Nicolas Cimbolini, Pierre-Paul Elena, Georges Gaudriault, Audrey Petit; Biocompatibility of MedinGel biodegradable drug delivery system in the eye. Invest. Ophthalmol. Vis. Sci. 2014;55(13):5273.

      Download citation file:

      © ARVO (1962-2015); The Authors (2016-present)

  • Supplements

Purpose: The purpose of this study was to investigate the biocompatibility of biodegradable in situ forming depots composed of a mixture of poly(lactide)-b-poly(ethylene glycol)-b-poly(lactide) (PLA-PEG-PLA) and methoxy-poly(ethylene glycol)-b-poly(lactide) (mPEG-PLA) after intravitreal administration in rabbits.

Methods: Two different MedinGel formulations were administered as single intravitreal 5-μl injections into the right eyes (RE) of healthy rabbits, using 27G needles. As control, animals also received 5-μl saline solution intravitreal injections of the left eyes (LE). Biocompatibility was monitored by slit lamp biomicroscopy with McDonald-Shadduck scoring, fundus evaluation and intraocular pressure assessment (IOP) for two weeks and, after sacrifice of the animals at 2 weeks, by macroscopic observations and ocular histopathology.

Results: There were no adverse effects related to body weight, body weight gain, food and water consumption. After intravitreal injection, the depots as well as the saline solutions induced a transient conjunctival chemosis and discharge for 24 hours, and conjunctival redness for 72 hours. No significant variation in IOP was observed in any of the animals during the duration of the study. Close to the injection site: retinal layers were disorganized, collagen fibers and cellular debris with macrophages were present. All these reactions were observed both in control and treated eyes. Ocular structures evaluated by histology examination disclosed no other damage after intravitreal injections of tested items. More data is also being generated on the biocompatibility of MedinGel depots after subconjunctival injection.

Conclusions: These results indicate that MedinGel depots administered intravitrealy were well tolerated. It demonstrates that this injectable biodegradable drug delivery system is a promising vehicle for ophthalmic applications.

Keywords: 688 retina • 763 vitreous • 474 conjunctiva  

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.